OncoMatch/Clinical Trials/NCT06421675
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Is NCT06421675 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Elranatamab for refractory multiple myeloma.
Treatment: Elranatamab — A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug (lenalidomide, pomalidomide)
An immunomodulatory drug (lenalidomide or pomalidomide)
Must have received: proteasome inhibitor (bortezomib, ixazomib, carfilzomib)
a proteasome inhibitor (bortezomib, ixazomib, carfilzomib)
Must have received: anti-CD38 drug (daratumumab, isatuximab)
an anti-CD38 drug (daratumumab or isatuximab)
Cannot have received: BCMA targeting agent
History of prior treatment with a BCMA targeting agent
Cannot have received: stem cell transplant
Exception: within 12 weeks prior to enrollment or active graft versus host disease
Stem cell transplant within 12 weeks prior to enrollment or active graft versus host disease
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≤ 1.0 x 10^9 /L; Platelet count ≤ 25 x 10^9 /L; Hemoglobin ≤ 8.0 g/dL
Kidney function
Creatinine clearance < 30 mL/min (according to the Cockcroft Gault formula, by 24-hour urine collection for creatinine clearance, or according to local institutional standard method)
Liver function
Serum AST and ALT > 2.5 x upper limit of normal (ULN); Total bilirubin > 2.0 x ULN (≥ 3.0 unless known to have Gilbert's disease)
Laboratory results ... ANC ≤ 1.0 x 10^9 /L ... Platelet count ≤ 25 x 10^9 /L ... Hemoglobin ≤ 8.0 g/dL ... Serum AST and ALT > 2.5 x ULN ... Creatinine clearance < 30 mL/min ... Total bilirubin > 2.0 x ULN (≥ 3.0 unless known to have Gilbert's disease)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify